GENESIS Biomed and FI Group create GENESIS Tech Transfer Boost, a new investment vehicle that will invest in early stage projects from healthcare research
...
26 April, 2022 / No comment
GENESIS Tech Transfer Boost is an investment vehicle created in 2022 and managed by the consulting firm GENESIS Biomed, with the aim of detecting and investing in early-stage projects in the biomedical sector, whether from hospitals or academic institutes.
The founding partners are GENESIS Biomed, FI Group and Crowd4Ventures, which are committing a total of €1M for the next 4 years. In addition, the total size of the vehicle can be increased through the current partners and the incorporation of new ones.
The creation of the investment vehicle will allow to identify projects in an solid ecosystem. In addition, they will be accompanied and managed from the early stages of the project, accelerating its arrival to the market.
The vehicle is positioned in the incubation area, targeting early-stage projects. It is agnostic in the biomedical field, investing in projects that fit into the vehicle’s life cycle, in terms of medtech, diagnostic, biotech and digital.
Tickets ranging from €25,000 to €100,000 will be invested, depending on the nature of each project and its needs. The vehicle is allowed to invest in pre-foundation phase of the selected projects.
GENESIS Biomed has validated the vehicle’s value proposition and investment model through a first vehicle, GENESIS Ventures I, which has invested in 13 projects and has a portfolio valuation of x3.37 factor to date.
